All In MedTech

Device Trial Radar · NCT02167659

Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema (PREVENT)

A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement in the Prevention of Lymphedema Following Locoregional Treatment for Breast Cancer (PREVENT)

Last checked: Nov 20, 2026Latest source record: Jan 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,201 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,201

Actual

Start

Jun 2014

Primary completion

Dec 31, 2020

Study completion Dec 31, 2020

Sponsor

Lead sponsor
ImpediMed LimitedNot on our public-company list
Sponsor type
Industry
Collaborators
Vanderbilt University; Macquarie University, Australia
First posted
Jun 19, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Based upon the current state of science, the investigators are proposing to conduct a randomized clinical trial in which participants are randomized post-surgery to either BIS or circumferential (tape) measurements for follow-up arm measurements. When patients in the BIS group have an L-Dex change that is ≥6.5 units higher than the pre-surgical baseline measure, and when patients in the tape measurement group have a volume change in the at-risk arm that is between ≥ 5% and \<10% above pre-surgical baselines (without similar change in non-at-risk arm), both will receive four weeks of 23-32 mm compression sleeve and gauntlet therapy.

Conditions

  • Lymphedema

Interventions

  • 23-32 mmHg compression sleeve with gauntletDevice

    A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and \<10% above pre-surgical baseline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of progression of lymphedemaTime frame: 3 years

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Jacksonville, Florida

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Louisville

    Louisville, Kentucky

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.